Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ACP1 | P24666 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.49 |
| ▸ | ALPL | P05186 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28134632 | 0.98 | KDR (0.53) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL11591505 | 0.79 | NPSR1 (0.57) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL11591503 | 0.79 | NPSR1 (0.57) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL28170955 | 0.79 | NPC1 (0.41) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL28152569 | 0.79 | NPC1 (0.41) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL28302813 | 0.78 | NPC1 (0.40) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL27805824 | 0.77 | ALDH1A1 (0.39) | KDRKDM4ERAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10133307 | 0.77 | NPC1 (0.61) | KDM4ERAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL349142 | 0.76 | KDR (0.55) | KDRNPSR1KDM4ERAB9ANPC1 | |
| SCHEMBL28067551 | 0.76 | ALDH1A1 (0.38) | KDRKDM4ERAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520127-A | Piperidinyl-substituted and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6 | TAKEDA PHARMACEUTICALS CO | 2019-11-29 | — | — | CN | claimed |
| CN-107001240-B | Dipeptidyl ketoamide compounds and their use for treating and/or preventing fat accumulation | 兰德施泰纳根梅德公司 | 2019-11-05 | — | — | CN | claimed |
| CN-107434782-B | A kind of synthetic method of 4- oxyquinoline ketone derivatives and its application in antitumor research | 重庆文理学院 | 2019-11-05 | — | — | CN | claimed |
| CN-106467541-B | Substituted quinolone analog derivative or its pharmaceutically acceptable salt or stereoisomer and its Pharmaceutical composition and application | 暨南大学 | 2019-04-05 | — | — | CN | claimed |
| CN-109563033-A | Aliphatic Prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2019-04-02 | — | — | CN | claimed |
| CN-109476637-A | heterocyclic Prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| CN-109384793-A | A kind of sulfur alcohol compound and its application with HDAC6 inhibitory activity | 沈阳药科大学 | 2019-02-26 | — | — | CN | claimed |
| CN-109310675-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2019-02-05 | — | — | CN | claimed |
| CN-109071525-A | dimeric compounds | 豪夫迈·罗氏有限公司 | 2018-12-21 | — | — | CN | claimed |
| CN-108884084-A | Cinnolines -4- amine compounds and its purposes in treating cancer | 阿斯利康(瑞典)有限公司 | 2018-11-23 | — | — | CN | claimed |
| CN-108430992-A | QUINOLINE-3-CARBOXAMIDES AS H-PGDS INHIBITORS | 阿斯特克斯医疗公司 | 2018-08-21 | — | — | CN | claimed |
| CN-105198786-B | Amides compound of aryl substitution and preparation method thereof, the pharmaceutical composition comprising it and its application | 中国医学科学院医药生物技术研究所 | 2018-06-29 | — | — | CN | claimed |
| CN-105073738-B | Quinoline and quinoxaline amide-type as sodium channel modulators | 沃泰克斯药物股份有限公司 | 2018-01-05 | — | — | CN | claimed |
| CN-107072985-A | Therapeutic inhibiting compound | 莱福斯希医药公司 | 2017-08-18 | — | — | CN | claimed |
| CN-103804352-B | Triazole phenethyl tetrahydroisoquinolicompounds compounds and its preparation method and application | 中国药科大学 | 2017-06-13 | — | — | CN | claimed |
| CN-103917525-B | The inhibitor of LRRK2 kinase activity | 依兰制药公司 | 2016-08-17 | — | — | CN | claimed |
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | claimed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | claimed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | KDR 3831/4885NPSR1 3298/4885KDM4E 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.